Skip to main content

Table 2 The incidence of CM and all-cause mortality among CrAg+ and CrAg- persons, and among persons with and without antifungal therapy

From: The prevalence of cryptococcal antigen (CrAg) and benefits of pre-emptive antifungal treatment among HIV-infected persons with CD4+ T-cell counts < 200 cells/μL: evidence based on a meta-analysis

 Number of reported studiesNumber of personsES (95%CI)I2P
Incidence of CM among CrAg + persons
 1.1 Incidence of CM among CrAg+ persons621180.03 (0.01, 0.05)62.3%0.021
Incidence of CM among persons with and without antifungal therapy
 2.1 Incidence of CM among persons with antifungal therapy610880.03 (0.01, 0.06)57.7%0.037
 2.2 Incidence of CM among persons without antifungal therapy410920.05 (0.02, 0.09)71.5%0.015
All-cause mortality in CrAg+ persons
 1.1 All-cause mortality among CrAg+ persons822650.14 (0.06, 0.22)94.5%0.000
All-cause mortality among persons who with and without antifungal therapy
 2.1 All-cause mortality among persons with antifungal therapy63960.17 (0.11, 0.24)58.3%0.035
 2.2 All-cause mortality among persons without antifungal therapy410920.10 (0.01, 0.19)93.2%0.000